Luigi Formisano, Associate Professor of Medical Oncology at the University of Naples Federico II, shared on LinkedIn:
“Pleased to share our group’s latest review, published in Critical Reviews in Oncology/Hematology:
Title: FGFR-Altered Urothelial Carcinoma in the EV–Pembrolizumab Era: Rationale and Emerging Data for Upfront Triplet Strategies
Authors: Claudia Maria Ascione, Raffaella Congi, Stella Feliciello, Carmine Caso, Felice Crocetto, Ciro Imbimbo, Alberto Servetto, Fabrizio Di Costanzo, Roberto Bianco, Daniela Esposito, Luigi Formisano
We explore the rationale and emerging evidence for integrating FGFR inhibitors with enfortumab vedotin – pembrolizumab, highlighting the potential of upfront triplet strategies and the questions that future clinical trials must address.
Many thanks to all co-authors for their contribution!”
You can also read:
EVOLUTE: Enfortumab Vedotin in Older Patients With Advanced Urothelial Carcinoma
